ArticleRespirology case reports2025
Economic Impact of Biologics for Severe Asthma: A Case Series of 14 Patients From Northern Malaysia.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Economic Impact of Biologics for Severe Asthma: A Case Series of 14 Patients From Northern Malaysia.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There remains a paucity of evidence from Asia on the cost-effectiveness of biologics for severe asthma. This pilot cost-offset analysis aims to evaluate the economic impact of adding biologics (omalizumab or benralizumab) to severe asthma standard care as a proof of concept for its cost-effectiveness, and to assess improvement in exacerbation rates and asthma control. Fourteen patients from the Severe Asthma Registry of Hospital Sultanah Bahiyah, Kedah who received biologics for at least 12 months from January 2018 to December 2024 were included. The economic impact of biologic treatment was evaluated by comparing the cost of biologic administration with the potential savings from reduced exacerbations requiring emergency department visits and hospital admission. Cost savings were observed with biologics, alongside reduced exacerbation and improved asthma control in real-world settings. Future research could explore a full cost-effectiveness analysis and a budget impact analysis to inform strategic pricing and reimbursement decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.